Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bacteriology
Data presented on Mycobacterial Cell Wall-DNA Complex
April 19th, 2005
Bioniche Life Sciences, Inc., (BNC), a research-based, technology-driven Canadian biopharmaceutical company, presented data from three studies using the company's proprietary Mycobacterial Cell Wall-DNA Complex (MCC) at the 2005 European Association of Urology 20th Congress in Istanbul, Turkey. MCC, trademarked Urocidin, is currently under development as a treatment for bladder cancer. The presentations were: 1) Mycobacterial Cell Wall-DNA Complex (MCC) Interacts Rapidly with Bladder Cancer Cells and Demonstrates Synergy with Gemcitabine 2) The Direct Anticancer Activity of Mycobacterial Cell Wall-DNA Complex...
Source: Cancer Weekly (2005-04-19)
|
